



## ResAppDx goes live with Alodokter in Indonesia

**Brisbane, Australia, 7 January 2022** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that its ResAppDx acute respiratory diagnostic test has been successfully implemented in Alodokter’s online telehealth platform in Indonesia and is now live on the platform.

The Alodokter platform connects more than 50,000 doctors and 1,500 hospitals and clinics with millions of Indonesian patients. It also provides a wide array of services around telemedicine such as offline doctor booking, insurance services, e-pharmacy and digital healthcare content.

**Suci Arumsari, President Director of Alodokter** said: *“What makes ResApp’s technology stand out is that you do not need any additional devices, you just need a smartphone. This type of smartphone-based technology is a real revolution for telemedicine as the overwhelming majority of patients do not own specialised healthcare devices. ResAppDx enables our doctors to diagnose a wider range of disease remotely and give more efficient treatment. This is particularly critical in a country like Indonesia where many people live far from a well-equipped healthcare facility.”*

**CEO and Managing Director of ResApp Health, Dr Tony Keating** said: *“We are excited to now have ResAppDx live on Alodokter’s platform, providing Alodokter’s doctors with an accurate way to assess patients who present with respiratory symptoms. Alodokter have been an excellent partner to work with during the integration and launch phases and we look forward to continuing the partnership as we scale into the opportunity to help improve the healthcare of the millions of Indonesians who rely on Alodokter for their healthcare.”*

###

### About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

**ResApp Health Limited** ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T +61 7 3724 0035 E [info@resapphealth.com.au](mailto:info@resapphealth.com.au) W [www.resapphealth.com.au](http://www.resapphealth.com.au)



**Contacts**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Executive Director, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*